肌層浸潤性膀胱癌新輔助化療的自身不足與應用局限

Disadvantages and limitations of neoadjuvant chemotherapy for invasive bladder cancer

ABSTRACT：For muscle-invasive bladder cancer （MIBC） patients，preoperative neoadjuvant chemotherapy （NAC） can reduce the tumor stage，treat micrometastases，prolong the median survival，and improve the prognosis.However，NAC is associated with side effects such as renal impairment，thromboembolism and drug toxicity.NAC itself suffers from deficiencies such as renal function impairment，thromboembolism，and drug toxicity.Its therapeutic efficacy is affected by factors such as tumor pathology type，DNA repair gene defects，whether it is primary MIBC，and TNM staging，so there are certain limitations in its use.Based on the cisplatin treatment regimen，more and more studies are exploring the limitations and shortcomings of NAC in MIBC treatment regimen.Therefore，this paper provides an overview and outlook of the application of NAC in MIBC treatment.

KEY WORDS：muscle invasive bladder cancer; cisplatin; neoadjuvant chemotherapy; radical cystectomy; disadvantage

摘要：對于肌層浸潤性膀胱癌（MIBC）患者，術前新輔助化療（NAC）可使腫瘤降期、治療微轉(zhuǎn)移灶，有效延長患者的中位生存期，改善預后。（剩余14340字）